Shuji Sawada1, Hayao Ozaki2,3, Toshiharu Natsume2,4, Pengyu Deng5, Toshinori Yoshihara5, Takashi Nakagata2,6, Takuya Osawa2,7, Yoshihiko Ishihara2,8, Tomoharu Kitada2,9, Ken Kimura10, Nobuhiro Sato11, Shuichi Machida12,13,14,15, Hisashi Naito2. 1. COI project center, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. 2. School of Health and Sports Science, Juntendo University, 1-1 Hirakagakuendai, Inzai, Chiba, 270-1695, Japan. 3. School of Sport and Health Science, Tokai Gakuen University, 21-233 Nishinohora, Ukigai, Miyoshi, Aichi, 470-0207, Japan. 4. Department of Human Structure & Function, Tokai University School of Medicine, 143 Shimokasuya, Iesehara, Kanagawa, 259-1193, Japan. 5. Graduate School of Health and Sports Science, Juntendo University, 1-1 Hirakagakuendai, Inzai, Chiba, 270-1695, Japan. 6. Department of Physical Activity Research, National Institutes of Biomedical Innovation, Health and Nutrition, 1-23-1 Toyama, Shinjuku-ku, Tokyo, 162-8636, Japan. 7. Faculty of Sports and Health Sciences, Japan Women's College of Physical Education, 8-19-1, Kitakarasuyama, Setagaya-ku, Chiba, Tokyo, 157-8565, Japan. 8. School of Science and Technology for Future Life, Tokyo Denki University, 5 Senju Asahi-cho, Adachi-ku, Tokyo, 120-8551, Japan. 9. Faculty of Business Administration, Seijoh University, 2-172 Fukinodai, Tokai City, Aichi, 476-8588, Japan. 10. School of Engineering, Tokyo Denki University, 5 Senju Asahi-cho, Adachi-ku, Tokyo, 120-8551, Japan. 11. Graduate School of Medicine, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. 12. COI project center, Juntendo University, 2-1-1 Hongo, Bunkyo-ku, Tokyo, 113-8421, Japan. machidas@juntendo.ac.jp. 13. School of Health and Sports Science, Juntendo University, 1-1 Hirakagakuendai, Inzai, Chiba, 270-1695, Japan. machidas@juntendo.ac.jp. 14. Graduate School of Health and Sports Science, Juntendo University, 1-1 Hirakagakuendai, Inzai, Chiba, 270-1695, Japan. machidas@juntendo.ac.jp. 15. Institute of Health and Sports Science & Medicine, Juntendo University, 1-1 Hirakagakuendai, Inzai, Chiba, 113-8421, Japan. machidas@juntendo.ac.jp.
Abstract
BACKGROUND: Low muscle strength has been focused on as an essential characteristic of sarcopenia, and the 30-s chair stand test (CS-30) could be a particularly useful test for assessing muscle strength. While it is speculated to be a beneficial tool for the assessment of sarcopenia, this remains to be verified. In this study, we examined the reliability and optimal diagnostic score of the CS-30 for assessing sarcopenia in elderly Japanese participants. METHODS: This cross-sectional study included 678 participants (443 females and 235 males) who underwent the test for sarcopenia as per the Asian Working Group for Sarcopenia (AWGS) 2019, the CS-30 test, and the isometric knee-extension muscle strength test. ROC analysis was used to estimate the optimal CS-30 scores at which sarcopenia was detected. RESULTS: CS-30 scores were positively associated with sarcopenia (OR: 0.88; 95% CI:0.82-0.93). The AUC of the CS-30 for sarcopenia definition were 0.84 (p < 0.001) for females and 0.80 (p < 0.001) for males. The optimal number of stands in the CS-30 that predicted sarcopenia was 15 for females (sensitivity, 76.4%; specificity, 76.8%) and 17 for males (sensitivity, 75.0%; specificity, 71.7%). CONCLUSIONS: The CS-30 was found to be a reliable test for sarcopenia screening in the elderly Japanese population.
BACKGROUND: Low muscle strength has been focused on as an essential characteristic of sarcopenia, and the 30-s chair stand test (CS-30) could be a particularly useful test for assessing muscle strength. While it is speculated to be a beneficial tool for the assessment of sarcopenia, this remains to be verified. In this study, we examined the reliability and optimal diagnostic score of the CS-30 for assessing sarcopenia in elderly Japanese participants. METHODS: This cross-sectional study included 678 participants (443 females and 235 males) who underwent the test for sarcopenia as per the Asian Working Group for Sarcopenia (AWGS) 2019, the CS-30 test, and the isometric knee-extension muscle strength test. ROC analysis was used to estimate the optimal CS-30 scores at which sarcopenia was detected. RESULTS:CS-30 scores were positively associated with sarcopenia (OR: 0.88; 95% CI:0.82-0.93). The AUC of the CS-30 for sarcopenia definition were 0.84 (p < 0.001) for females and 0.80 (p < 0.001) for males. The optimal number of stands in the CS-30 that predicted sarcopenia was 15 for females (sensitivity, 76.4%; specificity, 76.8%) and 17 for males (sensitivity, 75.0%; specificity, 71.7%). CONCLUSIONS: The CS-30 was found to be a reliable test for sarcopenia screening in the elderly Japanese population.
Authors: Laura Ghiotto; Valentina Muollo; Toni Tatangelo; Federico Schena; Andrea P Rossi Journal: Front Endocrinol (Lausanne) Date: 2022-07-28 Impact factor: 6.055